Turning to our international cannabis, we grew net revenue by 22% year over year to approximately $53 million and remained the No. 1 market leader in medical cannabis across Europe. Our annual growth during the fiscal 2024 was driven by increased sales in Germany, Poland, the U.K., Australia, and New Zealand. In Germany, we believe we're best positioned to capture a majority of the expected incremental growth in the cannabis medical market, which is projected to be approximately $3 billion in the medium term.
We continue to lead Canadian cannabis market share by almost 200 bps over the next competitor and have consistently been at the top of the industry for the past three years. From a regional perspective, Tilray was No. 1 across British Columbia, Alberta and Ontario, and Quebec provinces combined, which include over 80% of the Canadian population. And we've also led in all secondary markets. In Canadian cannabis volume, Tilray shipped approximately 60% more in kgs, reaching 140 metric tons. Our unit sales grew approximately 130% to almost 35 million units. In fiscal 2024, approximately 27% of our Canadian adult-use cannabis net sales revenue came from new innovation, which is a testament to our successful ability to innovate and launch new products. Main two drivers of growth in FY25 should be Germany (in particular, and Europe in general) and the US drinks business. Revenue guidance does not include potential future M&A.” The company is basing its guidance on the potential business in the beverage markets and the German cannabis market. CEO Irwin Simon also noted in the company’s earnings call that rescheduling in the U.S. would change things at Tilray. Simon said that he sees an opportunity in selling infused beverages in the U.S. Simon told investors on the company’s earnings call, “We also relaunched HiBall Energy Drinks on Amazon and plan to launch new hemp-derived delta-9 beverages strategically in selected markets, including Texas and New Jersey, where we can leverage our existing beverage distribution network. Our hemp-derived delta-9 formulations are complete, and we’re actively developing a target launch strategy to ensure maximum impact. He told investors that if Tiray could sell the THC beverages that it produces in Canada today in the U.S., it would be a large-sized business.